PD-1 PD-L1单抗在复发转移性鼻咽癌中的研究进展

鼻咽癌患者经放疗及同步辅助化疗后，临床转归有所改善，但肿瘤复发及远处转移仍为一项难题。近些年，免疫检查点抑制剂的发现为肿瘤的免疫治疗提供了新的选择。其中，程序性细胞死亡受体1（programmed cell death protein-1，PD-1）/程序性死亡受体配体1（programmed cell death 1-ligand，PD-L1）单抗受到广泛关注且已应用于临床治疗。本文就帕博利珠单抗、纳武利尤单抗、卡瑞利珠单抗和特瑞普利单抗等PD-1/PD-L1单抗在复发/转移性鼻咽癌中的研究进展进行综述。 

Research progress of PD-1/PD-L1 monoclonal antibodies in recurrent/metastatic nasopharyngeal carcinoma

Clinical outcomes of patients with nasopharyngeal carcinoma have improved after radiotherapy and concurrent adjuvant chemotherapy. However, tumor recurrence and distant metastasis remain a problem. In recent years, immune checkpoint inhibitors have provided new options for tumor immunotherapy. Among immune checkpoint inhibitors, programmed cell death protein-1 (PD-1)/ programmed cell death protein-ligand 1 (PD- L1) monoclonal antibodies have received widespread attention and have been used in clinical treatments. This article reviews the research progress of pembrolizumab, nivolizumab, carrelizumab, teriprizumab, and other PD-1/PD-L1 monoclonal antibodies in recurrent/metastatic nasopharyngeal carcinoma.